FY2026 EPS Forecast for Gilead Sciences Increased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Erste Group Bank raised their FY2026 earnings estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of ($0.41) per share for the year, up from their previous forecast of ($0.44). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.48) per share.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis.

GILD has been the topic of a number of other research reports. Barclays cut their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Morgan Stanley dropped their price objective on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Zacks Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, JPMorgan Chase & Co. increased their target price on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $159.81.

Gilead Sciences Stock Up 0.2%

GILD opened at $159.08 on Monday. The company has a fifty day moving average price of $149.65 and a two-hundred day moving average price of $139.13. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $160.51.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the insider directly owned 113,684 shares in the company, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 111,000 shares of company stock valued at $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth about $15,393,785,000. State Street Corp lifted its holdings in shares of Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Amundi lifted its holdings in shares of Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Gilead Sciences during the 2nd quarter valued at about $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst commentary suggests Gilead could be substantially undervalued if new oncology trial data validate the company’s pipeline and create a larger long-term growth opportunity. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
• Positive Sentiment: Gilead reached an agreement with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), improving potential access and commercial prospects for the primary biliary cholangitis treatment. Gilead Reaches Canadian Reimbursement Agreement for LYVDELZI
• Positive Sentiment: An analyst raised the company’s fiscal 2026 EPS forecast, providing a modest fundamental tailwind ahead of earnings. FY2026 EPS Forecast for Gilead Sciences Raised
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide therapies, potentially strengthening the company’s longer-term growth strategy and business-development profile. Gilead Deal Shows Big Pharma Appetite for Oral Peptides
• Neutral Sentiment: Gilead is preparing to report third-quarter results. Strong HIV sales, Yeztugo momentum and oncology developments could support the shares, but analysts also flag competitive pressure. Gilead Q3 Earnings Preview
• Neutral Sentiment: Wall Street’s pre-earnings estimates focus on revenue, earnings and operating metrics for the quarter ended September 2026; the reports offer expectations but do not represent released results. Gilead Q3 Wall Street Estimates
• Negative Sentiment: Exchange-traded funds were reported as net sellers of Gilead shares on October 23, indicating some short-term institutional selling pressure. ETFs Are Net Sellers of Gilead

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.